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Twice-Weekly Brincidofovir (CMX001) Shows Promising
Antiviral Activity in Immunocompromised Transplant
Recipients with Asymptomatic Adenovirus Viremia
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Herve Mommeja-Marin 4. 1 Cincinnati Children’s Hospital
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Background: Adenovirus (AdV) infection causes morbidity
and mortality in immunocompromised patients, particularly
in pediatric patients. There is no approved therapy for the
prevention, preemption or treatment of AdV infection.
Brincidofovir (BCV, CMX001), an orally bioavailable broad-
spectrum nucleotide analog, has demonstrated in vitropo-
tency against all AdV species tested, including those most
often associated with severe disease. Two recent clinical
trials initiated brincidofovir twiceweekly (BIW) in transplant
recipients who presented with AdV viremia and no evidence
of end-organ AdV disease.
Methods: Study 202 was a randomized, placebo-controlled
trial that evaluated BCV as preemptive treatment of asymp-
tomatic adenoviremia in hematopoietic cell transplant (HCT)
recipients. Study 350 was an open-label, expanded access
trial in immunocompromised patients with no alternative
therapeutic intervention. Adult subjects were treated with
BCV 100 mg BIW; pediatric subjects were treated with BCV 2
mg/kg BIW. AdV viremia was monitored weekly. Antiviral
responses and mortality results are reported.
Results: A total of 26 subjects in Study 202 (n¼14) and Study
350 (n¼12) received BCV BIW based on AdV viremia at
screening. Subjects ranged from 7 months to 68 years of age
and all but one were HCT recipients. AdV was detected at the
central laboratory in 21 subjects at the time of ﬁrst dose.
Baseline viremia (BL) ranged from 100 (the lower limit of
detection for the assay, LLOD) to 2.2 x 107 copies/mL (median
3700). AdV viremia decreased to LLOD for 67% (14 of 21)
subjects within the ﬁrst week of therapy; an additional 4
subjects (18 of 21, 86%) reached LLOD at some time during
treatment. High levels of AdV viremia (>1000 c/mL) detected
in 14 subjects decreased to LLOD in 79% (11 of 14) within a
median of 9 days of BCV, and with a mean decrease of 1.8
log10c/mL. Observed all-cause mortality during a median 8
weeks (range 3 to 47) of follow-up was 15% (4 of 26). Two of
the 4 subjects who died had undetectable AdV viremia at the
time of death.
Conclusions: High risk transplant patients receiving twice-
weekly brincidofovir had rapid decline in their AdV viremia,
with limited progression to all-cause mortality. BCV is a
promising therapy for AdV and further study is warranted.
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broad-spectrum antiviral in development for the prevention
of dsDNA viral infections in immunocompromised patients.
Since pediatric patients pose unique toxicity challenges and
dsDNA viral infections are common in this age group, we
undertook an analysis of the collective safety experience in
pediatric subjects receiving BCV.
Methods: All pediatric subjects (<18 years) received oral
BCV weekly or twice-weekly under EINDs, in the open-label
expanded access Study 350, and in placebo-controlled Study
202 for the preemptive treatment of adenovirus (AdV)
infection. In Study 202, BCV was administered with food and
guidance on the management of gastrointestinal (GI) dis-
turbances was provided to the investigators.
Results: 147 pediatric subjects (median 7 years, range 3
months to 17 years) received a median of 7 weeks of BCV
(range 1 to 44), with 45 subjects receiving at least 10 weeks
of 4 mg/kg/week. Subjects were predominantly hematopoi-
etic cell transplant (HCT) recipients. Consistent with data
from adult immunocompromised subjects, the most
frequently reported adverse events (AEs) were GI distur-
bances, with diarrhea of any grade reported in 48% of sub-
jects in Study 202 and 43% in Study 350 and EINDs. Grade 3/4
diarrhea was reported in 13% (Study 202) and 12% (Study
350) of subjects. Less than 10% of subjects across Studies 202
and 350 discontinued BCV for GI symptoms. Transient in-
creases in ALT were reported in 4% (Study 202) and 12%
(Study 350 and EINDs) of subjects, predominantly <5x ULN
(grade 2) and not requiring discontinuation of BCV. In Study
202, the incidence of GI and ALT events leading to study drug
discontinuation was not higher in the BCV group than in the
placebo group, although the interpretation of these data is
limited by the small sample size. Based on treatment emer-
gent laboratory abnormalities, no indications of renal toxicity
or hematologic toxicity including neutropenia were
observed, including subjects who received higher BCV dose
or longer durations of treatment.
Conclusions: A review of data from pediatric subjects
treated with brincidofovir did not indicate any previously
unidentiﬁed safety signals. In these subjects, as in adults,
there was no indication of hematologic or renal toxicity. The
safety and tolerability proﬁle in adults and pediatric patients
to date support the continued development of brincidofovir
as prevention for dsDNA viral diseases.107
Robust Vaccine Responses in Double-Unit Cord Blood
Transplantation (CBT) Recipients Despite Lack of Transfer
of Memory T and B Cells
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Introduction: CBT is now associated with comparable dis-
ease-free survival to that of adult donor transplantation.
However, given CB grafts lack memory T & B cells, the ability
of CBT recipients to respond to vaccines is of great interest.
Methods: We analyzed the proportion of surviving double-
unit CBT recipients undergoing vaccination & their responses
(seroconversion or >3x rise in titers) to primary series vac-
cines (tetanus, diphtheria, pertussis, H. inﬂuenzae, polio &
pneumococcus). Pneumococcal response was deﬁned as
